The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity

Cancer Biology and Therapy

Volumn 14, Issue 11, 2013, Pages 1032-1038

  Lin, JianMin ^a   Spidel, Jared L ^a   Maddage, Christopher J ^a   Rybinski, Katherine A ^a   Kennedy, Rina P ^a   Krauthauser, Candice L M ^a   Park, Young Chul ^a   Albone, Earl F ^a   Jacob, Sara ^a   Goserud, Matthew T ^a   Martinez, Bryon P ^a   Chao, Qimin ^a   Zhou, Yuhong ^a   Nicolaides, Nicholas C ^a   Kline, J Bradford ^a   Grasso, Luigi ^a  

^a Morphotek Inc   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; CD16a; Farletuzumab; FOLR1; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FARLETUZUMAB; FOLATE RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; OVARY CANCER;

ANTIBODY-DEPENDENT CELLULAR CYTOTOXICITY; CD16A; FARLETUZUMAB; FOLR1; OVARIAN CANCER;

ADENOCARCINOMA; ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; FEMALE; FOLATE RECEPTOR 1; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RECEPTORS, IGG;

EID: 84890016561     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.26106     Document Type: Article

References (34)

1. Garin-Chesa P, Campbell I, Saigo PE, Lewis JL Jr., Old LJ, Rettig WJ. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol 1993; 142:557-67; PMID:8434649
2. Toffoli G, Cernigoi C, Russo A, Gallo A, Bagnoli M, Boiocchi M. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997; 74:193-8; PMID:9133455; http://dx.doi.org/10.1002/(SICI)1097-0215(19970422)74: 2〈193::AIDIJC10〉 3.0.CO;2-F
3. Campbell IG, Jones TA, Foulkes WD, Trowsdale J. Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991; 51:5329-38; PMID:1717147
4. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, Zurawski VR Jr., Kamen BA. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 1992; 52:3396-401; PMID:1596899
5. O'Shannessy DJ, Somers EB, Smale R, Fu YS. Expression of folate receptor- α (FRA) in gynecologic malignancies and its relationship to the tumor type. Int J Gynecol Pathol 2013; 32:258-68; PMID:23518909; http://dx.doi.org/10. 1097/PGP.0b013e3182774562
6. O'Shannessy DJ, Yu G, Smale R, Fu YS, Singhal S, Thiel RP, Somers EB, Vachani A. Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance. Oncotarget 2012; 3:414-25; PMID:22547449
7. Ebel W, Routhier EL, Foley B, Jacob S, McDonough JM, Patel RK, Turchin HA, Chao Q, Kline JB, Old LJ, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007; 7:6; PMID:17346028
8. Figini M, Ferri R, Mezzanzanica D, Bagnoli M, Luison E, Miotti S, Canevari S. Reversion of transformed phenotype in ovarian cancer cells by intracellular expression of anti folate receptor antibodies. Gene Ther 2003; 10:1018-25; PMID:12776159; http://dx.doi.org/10.1038/sj.gt.3301962
9. Matsue H, Rothberg KG, Takashima A, Kamen BA, Anderson RG, Lacey SW. Folate receptor allows cells to grow in low concentrations of 5-methyltetrahydrofolate. Proc Natl Acad Sci U S A 1992; 89:6006-9; PMID:1631087; http://dx.doi.org/10.1073/pnas.89.13.6006
10. Bottero F, Tomassetti A, Canevari S, Miotti S, Ménard S, Colnaghi MI. Gene transfection and expression of the ovarian carcinoma marker folate binding protein on NIH/3T3 cells increases cell growth in vitro and in vivo. Cancer Res 1993; 53:5791-6; PMID:8242637
11. Ottone F, Miotti S, Bottini C, Bagnoli M, Perego P, Colnaghi MI, Ménard S. Relationship between folate-binding protein expression and cisplatin sensitivity in ovarian carcinoma cell lines. Br J Cancer 1997; 76:77-82; PMID:9218736; http://dx.doi.org/10.1038/bjc.1997.339
12. Konner JA, Bell-McGuinn KM, Sabbatini P, Hensley ML, Tew WP, Pandit-Taskar N, Vander Els N, Phillips MD, Schweizer C, Weil SC, et al. Farletuzumab, a humanized monoclonal antibody against folate receptor alpha, in epithelial ovarian cancer: a phase I study. Clin Cancer Res 2010; 16:5288-95; PMID:20855460; http://dx.doi.org/10.1158/1078-0432.CCR-10-0700
13. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol 2013; 129:452-8; PMID:23474348; http://dx.doi.org/10.1016/j.ygyno.2013.03.002
14. Koene HR, Kleijer M, Algra J, Roos D, von dem Borne AE, de Haas M. Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood 1997; 90:1109-14; PMID:9242542
15. Kamen BA, Smith AK. Farletuzumab, an anti-folate receptor α antibody, does not block binding of folate or anti-folates to receptor nor does it alter the potency of anti-folates in vitro. Cancer Chemother Pharmacol 2012; 70:113-20; PMID:22644798; http://dx.doi.org/10.1007/s00280-012-1890-2
16. Miotti S, Bagnoli M, Tomassetti A, Colnaghi MI, Canevari S. Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in deter-gent-resistant complexes from the ovary carcinoma cell line IGROV1. J Cell Sci 2000; 113:349-57; PMID:10633085
17. Mellor JD, Brown MP, Irving HR, Zalcberg JR, Dobrovic A. A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer. J Hematol Oncol 2013; 6:1; PMID:23286345; http://dx.doi.org/10.1186/1756-8722-6-1
18. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6:443-6; PMID:10742152; http://dx.doi.org/10.1038/74704
19. Bruckheimer EM, Fazenbaker CA, Gallagher S, Mulgrew K, Fuhrmann S, Coffman KT, Walsh W, Ready S, Cook K, Damschroder M, et al. Antibodydependent cell-mediated cytotoxicity effectorenhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia 2009; 11:509-17, 2, 517; PMID:19484140
20. Green SK, Karlsson MC, Ravetch JV, Kerbel RS. Disruption of cell-cell adhesion enhances antibodydependent cellular cytotoxicity: implications for anti-body-based therapeutics of cancer. Cancer Res 2002; 62:6891-900; PMID:12460904
21. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res 2008; 68:8049-57; PMID:18829563; http://dx.doi.org/10.1158/0008-5472. CAN-08-2268
22. Horton HM, Bernett MJ, Peipp M, Pong E, Karki S, Chu SY, Richards JO, Chen H, Repp R, Desjarlais JR, et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 2010; 116:3004-12; PMID:20616215; http://dx.doi.org/10.1182/blood-2010-01-265280
23. Stavenhagen JB, Gorlatov S, Tuaillon N, Rankin CT, Li H, Burke S, Huang L, Vijh S, Johnson S, Bonvini E, et al. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via lowaffinity activating Fcgamma receptors. Cancer Res 2007; 67:8882-90; PMID:17875730; http://dx.doi.org/10.1158/0008-5472.CAN-07- 0696
24. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70:4481-9; PMID:20484044; http://dx.doi.org/10.1158/0008-5472.CAN-09-3704
25. Baudino L, Shinohara Y, Nimmerjahn F, Furukawa J, Nakata M, Martínez-Soria E, Petry F, Ravetch JV, Nishimura S, Izui S. Crucial role of aspartic acid at position 265 in the CH2 domain for murine IgG2a and IgG2b Fc-associated effector functions. J Immunol 2008; 181:6664-9; PMID:18941257
26. Lund J, Takahashi N, Pound JD, Goodall M, Jefferis R. Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains. J Immunol 1996; 157:4963-9; PMID:8943402
27. Duncan AR, Woof JM, Partridge LJ, Burton DR, Winter G. Localization of the binding site for the human high-affinity Fc receptor on IgG. Nature 1988; 332:563-4; PMID:2965792; http://dx.doi.org/10.1038/332563a0
28. Negri FV, Musolino A, Naldi N, Bortesi B, Missale G, Laccabue D, Zerbini A, Camisa R, Chernyschova N, Bisagni G, et al. Role of immunoglobulin G fragment C receptor polymorphism-mediated antibodydependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy. Pharmacogenomics J 2013; •••: http://dx.doi.org/10.1038/tpj.2012.54; PMID:23296156
29. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26:1789-96; PMID:18347005; http://dx.doi.org/10.1200/JCO.2007.14.8957
30. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, NIH Publication No. 91-3242, 1991.
31. Duncan AR, Winter G. The binding site for C1q on IgG. Nature 1988; 332:738-40; PMID:3258649; http://dx.doi.org/10.1038/332738a0
32. Thommesen JE, Michaelsen TE, Løset GÅ, Sandlie I, Brekke OH. Lysine 322 in the human IgG3 C(H)2 domain is crucial for antibody dependent complement activation. Mol Immunol 2000; 37:995-1004; PMID:11395138; http://dx.doi.org/10.1016/S0161-5890(01)00010-4
33. Sarmay G, Lund J, Rozsnyay Z, Gergely J, Jefferis R. Mapping and comparison of the interaction sites on the Fc region of IgG responsible for triggering antibody dependent cellular cytotoxicity (ADCC) through different types of human Fc gamma receptor. Mol Immunol 1992; 29:633-9; PMID:1533898; http://dx.doi.org/10.1016/0161-5890(92)90200-H
34. O'Shannessy DJ, Somers EB, Albone E, Cheng X, Park YC, Tomkowicz BE, Hamuro Y, Kohl TO, Forsyth TM, Smale R, et al. Characterization of the human folate receptor alpha via novel antibody-based probes. Oncotarget 2011; 2:1227-43; PMID:22204844